With the expansive growth of the electronic health record in the past decade, the extraction of meaningful use metrics is vital in the transition to value-based care, said Vinay Kini, MD, MS, cardiologist at the UCHealth Heart and Vascular Center–Anschutz Medical Campus.
With the expansive growth of the electronic health record in the past decade, the extraction of meaningful use metrics is vital in the transition to value-based care, said Vinay Kini, MD, MS, cardiologist at the UCHealth Heart and Vascular Center—Anschutz Medical Campus.
Transcript
Your argument in the session “Great Debates in Quality and Outcomes” at this year’s American Heart Association meeting focuses on the electronic health record [EHR]. Can you discuss its growing presence in the transition to value-based care?
EHR uptake over the last 10 years after the Affordable Care Act has been almost universal. I think something like 96% of hospitals now use electronic health records. In thinking about the transition to value-based care, what really, I think EHR is going to be the focus of, is some of these quality metrics or meaningful use—is kind of the term that’s been used over the last several years. These are things that are quality or process measures that really need to be extracted from the EHR because they’re not things that can be measured on kind of a more global scale by administrative data. So, to give you an example, right now a process measure that should be able to be extracted through the EHR would be something like when a patient is admitted for a heart attack, did they get the appropriate testing–the appropriate referrals afterward, the appropriate medications and treatments. Those things should be easily extractable through the electronic health record. Some of the bigger things like 30-day mortality or 30-day readmissions after hospitalization for a heart attack–those things will likely still stay in the realm of kind of the administrative data sets.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More